SCHEMBL2115743

SCHEMBL2115743

Cn1cnc2nc[nH]c2c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
PIK3CG P48736 1/20 0.44
PIK3C3 Q8NEB9 1/20 0.44
ATAD2 Q6PL18 1/20 0.44
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
ADORA2B P29275 9/20 0.43
ADORA2A P29274 9/20 0.43
PDE4A P27815 8/20 0.43
PDE4B Q07343 8/20 0.43
PDE4C Q08493 8/20 0.43
PDE4D Q08499 8/20 0.43
ADORA3 P0DMS8 3/20 0.43
PIK3CD O00329 1/20 0.43
ALPL P05186 1/20 0.43
TMIGD3 P0DMS9 1/20 0.43
ADORA1 P30542 1/20 0.43
CYP2C19 P33261 1/20 0.43
HIF1A Q16665 1/20 0.43
LMNA P02545 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1866522 0.78 PDE4A (0.49) ALDH1A1ADORA2BADORA2APDE4APDE4B
SCHEMBL18560720 0.77 ALDH1A1 (0.52) ALDH1A1ATAD2ADORA2BADORA2APDE4A
SCHEMBL16513159 0.77 ALDH1A1 (0.52) ALDH1A1ATAD2ADORA2BADORA2APDE4A
SCHEMBL29950717 0.77 PIK3CG (0.53) ALDH1A1PIK3CGPIK3C3KDM4ENPC1
SCHEMBL2117284 0.77 CYP2C19 (0.48) ALDH1A1PIK3CGPIK3C3KDM4ENPC1
SCHEMBL8354950 0.77 ALDH1A1 (0.52) ALDH1A1ATAD2ADORA2BADORA2APDE4A
SCHEMBL94914 0.77 ALDH1A1 (0.52) ALDH1A1ATAD2ADORA2BADORA2APDE4A
SCHEMBL612165 0.77 ALDH1A1 (0.52) ALDH1A1ATAD2ADORA2BADORA2APDE4A
SCHEMBL7684288 0.75 ALDH1A1 (0.50) ALDH1A1KDM4ENPC1ADORA2BADORA2A
SCHEMBL7990063 0.73 ALDH1A1 (0.47) ALDH1A1PIK3CGPIK3C3KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 469 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595486-B2 Aptamers for personal health care applications THE PROCTER & GAMBLE COMPANY (US) 2026-04-07 US claimed
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease SOCIETE DES PRODUITS NESTLE S.A. (CH) 2026-03-24 US claimed
US-12584136-B2 Aptamers for personal health care applications THE PROCTER & GAMBLE COMPANY (US) 2026-03-24 US claimed
US-12559515-B2 Cap compounds and RNAS comprising the same HELIX NANOTECHNOLOGIES INC (US) 2026-02-24 US claimed
US-12359205-B2 Aptamers for personal health care applications THE PROCTER & GAMBLE COMPANY (US) 2025-07-15 US claimed
US-20250206770-A1 CAP COMPOUNDS AND RNAS COMPRISING THE SAME HELIX NANOTECHNOLOGIES INC 2025-06-26 US claimed
WO-2025137486-A1 CAP COMPOUNDS AND RNAS COMPRISING THE SAME HELIX NANOTECHNOLOGIES INC (US) 2025-06-26 WO claimed
EP-3664776-B1 APTAMERS FOR CONSUMER PRODUCT COMPOSITIONS PROCTER & GAMBLE (US) 2025-05-14 EP claimed
EP-4448767-A1 APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONS The Procter & Gamble Company (US) 2024-10-23 EP claimed
EP-4448768-A1 APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONS The Procter & Gamble Company (US) 2024-10-23 EP claimed
EP-3665282-A1 APTAMERS FOR ORAL CARE APPLICATIONS THE PROCTER & GAMBLE COMPANY (US) 2020-06-17 EP claimed
US-10676748-B2 Aptamers for consumer product compositions THE PROCTER & GAMBLE COMPANY (US) 2020-06-09 US claimed
WO-2019032795-A1 APTAMERS FOR ORAL CARE APPLICATIONS THE PROCTER & GAMBLE COMPANY (US) 2019-02-14 WO claimed
US-20190048348-A1 Aptamers For Consumer Product Compositions THE PROCTER & GAMBLE COMPANY 2019-02-14 US claimed
WO-2019032811-A1 APTAMERS FOR CONSUMER PRODUCT COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2019-02-14 WO claimed
US-20190048349-A1 APTAMERS FOR ORAL CARE APPLICATIONS NEOVENTURES BIOTECHNOLOGY INC. (CA) 2019-02-14 US claimed
EP-3401683-A1 DIAGNOSING METABOLIC DISEASE BY THE USE OF A BIOMARKER Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) 2018-11-14 EP claimed
CN-105548407-B The detection method of modified nucleoside in urine 杭州汉库医学检验所有限公司 2017-07-14 CN claimed
CN-105548407-A Detecting method for modified nucleoside in urine HANGZHOU HEALTH-BANK MEDICAL LABORATORY CO LTD 2016-05-04 CN claimed
WO-2016043661-A1 MODIFIED PEPTIDE NUCLEIC ACIDS AND THEIR USE NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2016-03-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584136-B2 Aptamers for personal health care applications HAVCR2, LDLR, ICAM1 ALDH1A1 2579/4885PIK3CG 4538/4885PIK3C3 4512/4885
US-20250206770-A1 CAP COMPOUNDS AND RNAS COMPRISING THE SAME RNGTT, RNMT, NSUN2 ALDH1A1 1939/4885PIK3CG 2400/4885PIK3C3 2399/4885
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease GLS, AADAT, FGF23 ALDH1A1 822/4885PIK3CG 2060/4885PIK3C3 3998/4885
US-12595486-B2 Aptamers for personal health care applications HAVCR2, EPCAM, ICAM1 ALDH1A1 1974/4885PIK3CG 4595/4885PIK3C3 4549/4885
US-12559515-B2 Cap compounds and RNAS comprising the same RNMT, RNGTT, NSUN2 ALDH1A1 2010/4885PIK3CG 2275/4885PIK3C3 2110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.